News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
DUSA Pharmaceuticals to End Skin Drug Deal With GlaxoSmithKline’s Stiefel Laboratories
October 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- DUSA Pharmaceuticals Inc (DUSA.O) sought to terminate an agreement with a unit of GlaxoSmithKline PLC (GSK.L) to market and distribute its drug to treat scaly patches on the skin, in Latin America.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
South America
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Mergers & acquisitions
Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity
August 7, 2025
·
2 min read
·
Tristan Manalac
Earnings
Lilly Faces Triple Threat of Drug Pricing Pressure as CEO Emphasizes Value
August 7, 2025
·
3 min read
·
Annalee Armstrong
Cancer
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds
August 7, 2025
·
2 min read
·
Tristan Manalac
Earnings
Despite Safety Drama, Sarepta Beats Q2 Estimates—But No Thanks to Elevidys Sales
August 7, 2025
·
2 min read
·
Tristan Manalac
